Edwards Lifesciences Corporation

NYSE:EW Rapport sur les actions

Capitalisation boursière : US$41.5b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Edwards Lifesciences Croissance future

Future contrôle des critères 2/6

Edwards Lifesciences devrait augmenter ses bénéfices et son chiffre d'affaires de 7.5% et de 8.4% par an respectivement. Le BPA devrait croître de de 5.3% par an. Le rendement des capitaux propres devrait être 23.9% dans 3 ans.

Informations clés

7.5%

Taux de croissance des bénéfices

5.3%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices17.4%
Taux de croissance des recettes8.4%
Rendement futur des capitaux propres23.9%
Couverture par les analystes

Good

Dernière mise à jour16 Aug 2024

Mises à jour récentes de la croissance future

Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47

Feb 08
Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47

Recent updates

Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?

Aug 17
Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?

Edwards Lifesciences Q2: Buy The Dip Amid Guidance Cut

Jul 26

Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Jul 26
Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Why Investors Shouldn't Be Surprised By Edwards Lifesciences Corporation's (NYSE:EW) P/E

Jul 12
Why Investors Shouldn't Be Surprised By Edwards Lifesciences Corporation's (NYSE:EW) P/E

Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?

Jun 24
Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?

Edwards Lifesciences Corp Looks Bullish (Technical Analysis)

Jun 22

Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future

May 13
Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future

Edwards Lifesciences: EPS Acceleration, Shares Poised To Rally (Rating Upgrade)

May 09

When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)?

Apr 29
When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)?

Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Apr 15
Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Edwards Lifesciences Corporation's (NYSE:EW) Popularity With Investors Is Clear

Apr 01
Edwards Lifesciences Corporation's (NYSE:EW) Popularity With Investors Is Clear

Edwards Lifesciences' (NYSE:EW) Soft Earnings Don't Show The Whole Picture

Feb 21
Edwards Lifesciences' (NYSE:EW) Soft Earnings Don't Show The Whole Picture

Edwards Lifesciences: EVOQUE FDA Approval; Critical Care Spin-Off (Rating Maintained)

Feb 14

Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47

Feb 08
Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47

Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly

Jan 28
Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly

The Returns At Edwards Lifesciences (NYSE:EW) Aren't Growing

Jan 14
The Returns At Edwards Lifesciences (NYSE:EW) Aren't Growing

Edwards Lifesciences: Undervalued With A Substantial Upside Potential

Jan 09

Edwards Lifesciences Corporation's (NYSE:EW) Share Price Not Quite Adding Up

Dec 31
Edwards Lifesciences Corporation's (NYSE:EW) Share Price Not Quite Adding Up

Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)

Dec 17
Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)

Edwards Lifesciences: Sector Derating A Bigger Threat Than Competition Or Slowing Markets

Oct 26

Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?

Oct 23
Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?

Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?

Oct 09
Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?

Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value

Sep 26
Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value

A Look At The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Sep 11
A Look At The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Edwards Lifesciences: Rising Dominance In Structural Heart Disease

Aug 21

Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?

Jul 16
Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?

Is It Too Late To Consider Buying Edwards Lifesciences Corporation (NYSE:EW)?

Jun 30
Is It Too Late To Consider Buying Edwards Lifesciences Corporation (NYSE:EW)?

Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value

Jun 15
Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value

Edwards Lifesciences: Valuation Premium Earned, But Shares Are Not Cheap, Technicals Mixed

Jun 12

Are Edwards Lifesciences Corporation (NYSE:EW) Investors Paying Above The Intrinsic Value?

May 31
Are Edwards Lifesciences Corporation (NYSE:EW) Investors Paying Above The Intrinsic Value?

Prévisions de croissance des bénéfices et des revenus

NYSE:EW - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/20267,7021,9561,6852,02015
12/31/20257,0431,7871,5981,83516
12/31/20246,4811,5301,3761,71318
6/30/20246,2041,540552866N/A
3/31/20246,1141,428251528N/A
12/31/20236,0051,402630896N/A
9/30/20235,3621,3417751,042N/A
6/30/20235,2011,300669940N/A
3/31/20235,2791,4519721,239N/A
12/31/20225,3821,5229531,218N/A
9/30/20225,3641,4591,0401,309N/A
6/30/20225,3551,4551,2611,531N/A
3/31/20225,3571,5391,4281,725N/A
12/31/20215,2331,5031,4021,732N/A
9/30/20215,0951,4771,4091,758N/A
6/30/20214,9251,4621,0501,443N/A
3/31/20214,4748517171,148N/A
12/31/20204,3868236471,054N/A
9/30/20204,3697946921,057N/A
6/30/20204,3227449411,279N/A
3/31/20204,4841,1081,0871,389N/A
12/31/20194,3481,0479051,183N/A
9/30/20194,1527748091,073N/A
6/30/20193,964725705978N/A
3/31/20193,821765523777N/A
12/31/20183,723722685927N/A
9/30/20183,634712754998N/A
6/30/20183,549657772966N/A
3/31/20183,447560N/A1,024N/A
12/31/20173,435584N/A1,001N/A
9/30/20173,315745N/A838N/A
6/30/20173,232716N/A733N/A
3/31/20173,150657N/A726N/A
12/31/20162,964570N/A704N/A
9/30/20162,867552N/A607N/A
6/30/20162,743528N/A604N/A
3/31/20162,601515N/A584N/A
12/31/20152,494495N/A550N/A
9/30/20152,441463N/A539N/A
6/30/20152,433440N/A349N/A
3/31/20152,391874N/A957N/A
12/31/20142,323811N/A1,022N/A
9/30/20142,241777N/A1,040N/A
6/30/20142,129759N/A1,160N/A
3/31/20142,071306N/A511N/A
12/31/20132,046389N/A473N/A
9/30/20132,020405N/A476N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de EW ( 7.5% par an) est supérieure au taux d'épargne ( 2.5% ).

Bénéfices vs marché: Les bénéfices de EW ( 7.5% par an) devraient croître plus lentement que le marché US ( 15.1% par an).

Croissance élevée des bénéfices: Les bénéfices de EW devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de EW ( 8.4% par an) devrait croître plus lentement que le marché de US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de EW ( 8.4% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de EW devrait être élevé dans 3 ans ( 23.9 %)

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y